Search results
Showing 8146 to 8160 of 8941 results
Discontinued Reference number: GID-TA11146
Discontinued Reference number: GID-TA11343
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Discontinued Reference number: GID-TA11086
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Discontinued Reference number: GID-TA11228
Discontinued Reference number: GID-TA11466
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Discontinued Reference number: GID-TA11442
Discontinued Reference number: GID-TA11277
Discontinued Reference number: GID-TA11486
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
Discontinued Reference number: GID-TA11128
Discontinued Reference number: GID-TA11351
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]
Discontinued Reference number: GID-TA11647
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).